Tofacitinib in alopecia areata and HIV: A curious intersection of immunomodulation, hair regrowth, and hypertrichosis.

Abstract

Tofacitinib is a Janus kinase 3 (JAK3) inhibitor effective in treating alopecia areata (AA) by promoting hair regrowth. Its mechanism may involve upregulation of vascular endothelial growth factor (VEGF) and reduction of inflammation. However, the range of effects, particularly on hair growth in specific populations, remains under-investigated. We describe a patient with HIV, well-controlled on antiretroviral therapy, who developed hirsutism after starting tofacitinib for AA. This unexpected side effect of hypertrichosis was completely resolved after discontinuing the medication and undergoing a single session of laser hair removal (LHR). This case highlights the potential for unusual hair growth patterns associated with tofacitinib treatment in patients with immune dysregulation. Monitoring and management strategies for such side effects are discussed. This case highlights the potential for unusual hair growth patterns associated with tofacitinib treatment in patients with immune dysregulation. Monitoring and management strategies for such side effects are discussed. The case emphasizes the need for careful monitoring of hair growth and other potential side effects in patients on tofacitinib, especially those with underlying immune-modulating conditions. It also suggests that LHR can be an effective treatment for medication-induced hirsutism.